Medicine Press release

Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of "LEQEMBI(R)" (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly(R) in the EU) in Japan.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly(R) in the EU) in Japan.
More info..

Fujitsu Japan Limited and JMDC Inc. today announced the commencement of a collaboration aimed at advancing medical care and contributing to the establishment of a sustainable healthcare system in Japan.
More info..

TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, announced today that it has established a total solution system capable of supporting all processes in the contract manufacturing business for various test kits including in vitro diagnostics.
More info..

TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, announced today that it has established a total solution system capable of supporting all processes in the contract manufacturing business for various test kits including in vitro diagnostics.
More info..

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd.
More info..

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd.
More info..

Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced publication of the EAGLE Trial1 - a multicenter randomized controlled study evaluating the CADDIE(TM) device, the first cloud-based Computer-Aided Detection (CADe) application for real-time polyp detection during colonoscopy that is both FDA-cleared and CE-marked.
More info..

Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced publication of the EAGLE Trial1 - a multicenter randomized controlled study evaluating the CADDIE(TM) device, the first cloud-based Computer-Aided Detection (CADe) application for real-time polyp detection during colonoscopy that is both FDA-cleared and CE-marked.
More info..